8-K: Kura Oncology Q2 2025: Ziftomenib NDA Priority Review

Kura Oncology reports Q2 2025 financial results, highlights FDA Priority Review for ziftomenib in R/R NPM1-m AML with a November 30, 2025 PDUFA date, and outlines commercialization readiness.

Summary

• Collaboration revenue for the second quarter of 2025 was $15.3 million, compared to no revenue for the second quarter of 2024.
• Research and development expenses for the second quarter of 2025 were $62.8 million, compared to $39.7 million for the second quarter of 2024.
• General and administrative expenses for the second quarter of 2025 were $25.2 million, compared to $16.7 million for the second quarter of 2024.
• Net loss for the second quarter of 2025 was $66.1 million, compared to a net loss of $50.8 million for the second quarter of 2024.
• Cash, cash equivalents, and short-term investments totaled $630.7 million as of June 30, 2025, a decrease from $727.4 million as of December 31, 2024.
• The FDA granted Priority Review for the New Drug Application (NDA) for ziftomenib in adults with relapsed or refractory (R/R) NPM1-mutant (NPM1-m) Acute Myeloid Leukemia (AML), setting a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025.
• Commercial readiness activities for ziftomenib are advancing, with the hiring and onboarding of the U.S. field sales team now complete.
• Positive results from the KOMET-001 pivotal trial of ziftomenib in R/R NPM1-m AML were presented, showing a complete remission (CR) plus CR with partial hematologic recovery (CRh) rate of 23%.
• Clinical data from the Phase 1b expansion cohort of KOMET-007 evaluating ziftomenib in combination with intensive chemotherapy in newly diagnosed NPM1-m and KMT2A-rearranged AML showed high rates of CR and measurable residual disease (MRD) negativity.
• Two Phase 3 studies (KOMET-017-IC and NIC) for ziftomenib in newly diagnosed AML are on track to start in the second half of 2025.
• A next-generation menin inhibitor designed for the treatment of Type 1 and Type 2 diabetes and menin-dependent cardiometabolic indications has been nominated for evaluation.
• Three clinical abstracts from the farnesyl transferase inhibitor (FTI) development program, including first clinical data on KO-2806, were accepted for presentation at the 2025 ESMO Congress.
• Current cash, together with anticipated collaboration agreement payments, is expected to support ziftomenib commercialization through the frontline AML combination setting and fund operating expenses into 2027.

Sentiment

Score: 8

Explanation: The filing presents a strong positive outlook driven by the FDA's Priority Review for ziftomenib, robust clinical data, advanced commercialization efforts, and a solid cash position. While expenses and net loss increased, these are typical for a clinical-stage biopharmaceutical company nearing commercialization and conducting multiple trials. The diversification into diabetes also adds long-term potential.

Positives

• The FDA granted Priority Review for ziftomenib NDA in R/R NPM1-m AML, setting a PDUFA target action date of November 30, 2025, indicating an accelerated review timeline.
• Ziftomenib is the only menin inhibitor to receive Breakthrough Therapy Designation (BTD) for the R/R NPM1-m AML indication, highlighting its potential significance.
• Commercial readiness activities are well underway, including the successful completion of hiring for the U.S. field sales team, positioning for a strong market launch.
• Positive results from the KOMET-001 pivotal trial demonstrated a 23% CR+CRh rate in heavily pretreated R/R NPM1-m AML patients, an improvement over historical controls, with a favorable benefit-risk profile.
• High rates of CR and MRD negativity were observed in the KOMET-007 Phase 1b expansion cohort for ziftomenib in combination with intensive chemotherapy in newly diagnosed NPM1-m and KMT2A-rearranged AML.
• Cash, cash equivalents, and short-term investments of $630.7 million as of June 30, 2025, are projected to fund operations into 2027 and, combined with anticipated collaboration payments, support ziftomenib commercialization through the frontline AML combination setting.
• Initiation of two Phase 3 registrational trials (KOMET-017) in newly diagnosed AML is on track for the second half of 2025, expanding ziftomenib's potential market.
• Nomination of a next-generation menin inhibitor for diabetes and cardiometabolic indications demonstrates pipeline diversification and potential for future growth beyond oncology.
• Three clinical abstracts from the FTI program, including first clinical data for KO-2806, were accepted for presentation at the 2025 ESMO Congress, showcasing ongoing pipeline progress.
• Collaboration revenue of $15.3 million was recognized in Q2 2025, compared to no revenue in Q2 2024, reflecting the Kyowa Kirin partnership.

Negatives

• Net loss increased to $66.1 million in Q2 2025 from $50.8 million in Q2 2024, reflecting increased operational costs.
• Research and development expenses rose to $62.8 million in Q2 2025 from $39.7 million in Q2 2024, driven by ongoing clinical trials and development activities.
• General and administrative expenses increased to $25.2 million in Q2 2025 from $16.7 million in Q2 2024, likely due to commercialization readiness efforts.
• Cash, cash equivalents, and short-term investments decreased to $630.7 million as of June 30, 2025, from $727.4 million as of December 31, 2024, indicating cash burn.

Risks

• Compounds that appeared promising in early research or clinical trials may not demonstrate safety and/or efficacy in later preclinical studies or clinical trials.
• Kura may not obtain approval to market its product candidates.
• Uncertainties are associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies.
• Risks are associated with reliance on third parties to successfully conduct clinical trials.
• Risks are associated with reliance on outside financing to meet capital requirements.
• The collaboration with Kyowa Kirin may be unsuccessful.
• Other risks are associated with the process of discovering, developing, and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.

Future Outlook

Kura Oncology anticipates continued regulatory interactions with the FDA leading up to the November 30, 2025 PDUFA target action date for ziftomenib. The company plans to initiate two Phase 3 registration-enabling trials (KOMET-017) in frontline AML in the second half of 2025. Additionally, preliminary clinical data from the KOMET-007 Phase 1b expansion cohort and data from the FIT-001 Phase 1 trial and KURRENT-HN trial are expected to be presented in the second half of 2025, including at the 2025 ESMO Congress. The company believes its current cash, combined with anticipated collaboration payments, will fund operations into 2027 and support ziftomenib commercialization through the frontline AML combination setting.

Management Comments

• "FDAs acceptance of our NDA for ziftomenib represents another important step toward addressing a high unmet need in patients with relapsed or refractory NPM1-mutant AML."
• "As a menin inhibitor, ziftomenib targets a fundamental disease driver in certain genetically defined subsets of AML, and along with our partners at Kyowa Kirin, we are committed to advancing ziftomenib as a potential therapy for patients throughout the continuum of care."
• "With preparations underway for commercialization, upcoming initiation of two registrational trials of ziftomenib in the frontline setting and a strong pipeline to support future growth, we believe Kura is well-positioned to deliver meaningful benefit to patients and long-term value to stakeholders."

Industry Context

Kura Oncology operates in the highly competitive and innovative precision medicine oncology sector, focusing on genetically defined subsets of cancer. The FDA's Priority Review for ziftomenib in R/R NPM1-m AML highlights the significant unmet need in this patient population, where current treatment options are limited. The development of menin inhibitors like ziftomenib represents a targeted approach to AML, aligning with broader industry trends towards therapies that address specific disease drivers. The expansion into diabetes with a next-generation menin inhibitor also indicates a strategic diversification into cardiometabolic indications, leveraging core scientific expertise to address other high-need areas.

Comparison to Industry Standards

• The KOMET-001 pivotal trial achieved a complete remission (CR) plus CR with partial hematologic recovery (CRh) rate of 23%, which is noted as an improvement over historical controls in a heavily pretreated patient population with limited survival and few treatment options.
• Ziftomenib is the only menin inhibitor to receive Breakthrough Therapy Designation (BTD) for R/R NPM1-m AML, distinguishing it from other therapies in development.
• High rates of CR and measurable residual disease (MRD) negativity with ziftomenib in combination with intensive chemotherapy in newly diagnosed NPM1-m and KMT2A-rearranged AML (68% of NPM1-m and 83% of KMT2A-r patients reaching MRD-negative status) suggest a strong efficacy profile compared to standard treatments, particularly given the ability for patients to remain on treatment without interruption or added myelosuppression.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive regulatory progress, strong clinical data, and commercialization readiness for ziftomenib. Increased R&D and G&A expenses, and net loss, are expected for a company in this stage, but the extended cash runway mitigates immediate dilution concerns.
• Patients: Significant positive impact with the potential approval of ziftomenib, offering a new, targeted treatment option for R/R NPM1-m AML, a population with high unmet medical need. Expansion into frontline AML and diabetes also promises future therapeutic options.
• Employees: Positive impact from commercialization readiness, including hiring of the U.S. field sales team, indicating growth and job security.
• Kyowa Kirin (Partner): Continued collaboration and progress towards commercialization of ziftomenib strengthens the partnership.
• Regulatory Authorities (FDA): Ongoing interactions and adherence to regulatory timelines are crucial for successful drug approval.

Next Steps

• Continued regulatory interactions with the FDA ahead of the November 30, 2025 PDUFA target action date for ziftomenib as a monotherapy for adult patients with relapsed or refractory NPM1-m AML.
• Initiate KOMET-017, two independent Phase 3 registration-enabling trials in frontline intensive chemotherapy and non-intensive chemotherapy AML settings, in the second half of 2025.
• Present preliminary clinical data from the KOMET-007 Phase 1b expansion cohort evaluating ziftomenib in combination with venetoclax and azacitidine in the second half of 2025.
• Initiate one or more FIT-001 expansion cohorts of KO-2806 and cabozantinib in patients with advanced renal cell carcinoma in the second half of 2025.
• Present data from the FIT-001 Phase 1 trial evaluating KO-2806 and cabozantinib in patients with renal cell carcinoma at the 2025 ESMO Congress in October 2025.
• Present data from the FIT-001 Phase 1 monotherapy dose escalation of KO-2806 in patients with RAS-mutant solid tumors at the 2025 ESMO Congress in October 2025.
• Present data from the KURRENT-HN trial evaluating tipifarnib and alpelisib in PIK3CA-dependent HNSCC at the 2025 ESMO Congress in October 2025.
• Announce development plans and timelines for the next-generation menin inhibitor for diabetes in a future update.

Key Dates

Recommendation

The FDA's grant of Priority Review for ziftomenib, coupled with a PDUFA target action date in November 2025, significantly de-risks the lead asset and accelerates its path to market. Positive clinical data from KOMET-001 and KOMET-007 trials further validate ziftomenib's efficacy and favorable safety profile in a high unmet need AML population. The company's robust cash position, extended into 2027 with anticipated collaboration payments, provides ample runway for commercialization and continued pipeline development, including two Phase 3 trials in frontline AML and a novel menin inhibitor for diabetes. While expenses have increased, this is a necessary investment for a biopharmaceutical company nearing commercial launch and expanding its clinical programs. The overall outlook is highly favorable, suggesting strong potential for significant value creation.

Keywords

Kura Oncology, KURA, Ziftomenib, AML, Acute Myeloid Leukemia, NPM1-m, Menin Inhibitor, FDA Priority Review, PDUFA, Oncology, Biopharmaceutical, Clinical Trials, KOMET-001, KOMET-007, KOMET-017, KO-2806, Farnesyl Transferase Inhibitor, FTI, ESMO Congress, Kyowa Kirin, Financial Results, Q2 2025, Drug Development, Precision Medicine, Cancer Treatment, Relapsed/Refractory AML, Newly Diagnosed AML, Diabetes, Cardiometabolic